LQDA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Liquidia Corp (LQDA) shows potential for long-term growth, but given the user's beginner level, long-term strategy, and impatience for optimal entry points, it is recommended to hold off on buying at this time. The stock lacks strong proprietary trading signals, and while there are positive catalysts, the financial performance and insider activity raise concerns.
The technical indicators show a bullish trend with MACD above 0 and expanding, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the RSI in a neutral zone at 56.353. The stock is trading near its pivot level of 36.413, with resistance at 38.113 and support at 34.713.
Analysts have raised price targets significantly, with Wells Fargo increasing to $51 and H.C. Wainwright to $55, citing strong market potential and impressive Q4 earnings.
The company achieved a 3054.65% YoY revenue increase in Q4 2025, driven by the successful launch of YUTREPIA.
Insider selling by the Chief Medical Officer, who sold shares worth $1.28 million, could indicate a lack of confidence in near-term price growth.
The company reported a net loss of $68.9 million in 2025 despite strong revenue growth.
The stock's historical trend suggests a potential decline of -3.49% in the next week and -2.16% in the next month.
In Q4 2025, revenue surged by 3054.65% YoY to $92.02 million, but net income dropped by -140.13% YoY to $14.55 million, and EPS fell by -139.53% YoY to 0.17. Gross margin improved significantly to 92.33%, up 72.32% YoY, indicating operational efficiency despite profitability concerns.
Analysts are optimistic about Liquidia's long-term potential, with multiple firms raising price targets and maintaining positive ratings. However, there is some divergence, as Oppenheimer maintains an Underperform rating despite raising its price target.
